We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+0.6%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$112M
AUM Growth
-$4.46M
Cap. Flow
-$3.52M
Cap. Flow %
-3.14%
Top 10 Hldgs %
40.26%
Holding
80
New
27
Increased
7
Reduced
10
Closed
28

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$4.23M
2
CABA icon
Cabaletta Bio
CABA
+$3.68M
3
AUTL
Autolus Therapeutics
AUTL
+$3.62M
4
AMGN icon
Amgen
AMGN
+$3.47M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$3.41M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$4.64M
2
RDY icon
Dr. Reddy's Laboratories
RDY
+$3.56M
3
RNAM
Avidity Biosciences
RNAM
+$3.45M
4
CLDX icon
Celldex Therapeutics
CLDX
+$2.98M
5
GERN icon
Geron
GERN
+$2.93M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.06T
$8.78M 7.82%
9,700
– –
SRPT icon
2
Sarepta Therapeutics
SRPT
$1.67B
$5.2M 4.63%
+32,900
New +$4.23M
ONC
3
BeOne Medicines Ltd
ONC
$33.9B
$4.74M 4.22%
33,200
-3,600
-10% -$555K
TGTX icon
4
TG Therapeutics
TGTX
$8.14B
$4.48M 3.99%
251,600
+21,300
+9% +$340K
CI icon
5
Cigna
CI
$76.2B
$4.03M 3.59%
12,200
-3,100
-20% -$1.07M
CRBP icon
6
Corbus Pharmaceuticals
CRBP
$171M
$3.84M 3.42%
84,790
-3,056
-3% -$129K
INSM icon
7
Insmed
INSM
$23.1B
$3.81M 3.39%
56,800
-14,900
-21% -$578K
AMGN icon
8
Amgen
AMGN
$199B
$3.69M 3.28%
+11,800
New +$3.47M
TVTX icon
9
Travere Therapeutics
TVTX
$5.2B
$3.64M 3.24%
443,379
+80,892
+22% +$545K
MDGL icon
10
Madrigal Pharmaceuticals
MDGL
$12.5B
$3.03M 2.69%
10,800
+2,900
+37% +$690K
AVDL
11
DELISTED
Avadel Pharmaceuticals
AVDL
$2.94M 2.62%
+209,092
New +$3.41M
DXCM icon
12
DexCom
DXCM
$27.2B
$2.94M 2.62%
25,928
+1,100
+4% +$139K
AUTL
13
Autolus Therapeutics
AUTL
$386M
$2.92M 2.6%
+839,472
New +$3.62M
ISRG icon
14
Intuitive Surgical
ISRG
$118B
$2.83M 2.52%
6,358
– –
RDY icon
15
Dr. Reddy's Laboratories
RDY
$9.73B
$2.77M 2.46%
181,500
-248,500
-58% -$3.56M
IRON icon
16
Disc Medicine
IRON
$2.86B
$2.75M 2.45%
+61,000
New +$2.07M
ASND icon
17
Ascendis Pharma A/S
ASND
$16.7B
$2.73M 2.43%
+20,000
New +$2.72M
KURA icon
18
Kura Oncology
KURA
$924M
$2.71M 2.42%
+131,742
New +$2.71M
MRUS
19
DELISTED
Merus
MRUS
$2.67M 2.38%
+45,100
New +$2.18M
MASI
20
DELISTED
Masimo
MASI
$2.49M 2.22%
+19,800
New +$2.61M
CNTA
21
DELISTED
Centessa Pharmaceuticals
CNTA
$2.48M 2.21%
274,900
– –
WVE icon
22
Wave Life Sciences
WVE
$1.09B
$2.44M 2.17%
+488,135
New +$2.78M
GH icon
23
Guardant Health
GH
$20B
$2.28M 2.03%
79,000
– –
CABA icon
24
Cabaletta Bio
CABA
$445M
$2.25M 2%
+300,200
New +$3.68M
ARVN icon
25
Arvinas
ARVN
$529M
$2.19M 1.95%
+82,400
New +$2.63M
1
2 3 4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
MUAMU
Mitsubishi UFJ Asset Management (UK) London, United Kingdom $193M AUM 37.43% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
BW
BostonPremier Wealth Hanover, Massachusetts $194M AUM 20.19% 1-Year Est. Return
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
CWRP
Cassady Wealth & Retirement Planning Henderson, Nevada $193M AUM

Exome Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Exome Asset Management held 80 positions worth $112M, down 3.8% from $117M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Exome Asset Management withdrew a net $3.52M in Q2 2024, closing 28 positions and reducing 10 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $4.64M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Exome Asset Management opened a new position in Sarepta Therapeutics worth $5.2M.

  • Exome Asset Management's largest Q2 2024 buy was Sarepta Therapeutics: 32,900 shares worth $5.2M.
  • Exome Asset Management added most to BridgeBio Pharma in Q2 2024, an estimated $823K increase.
  • Exome Asset Management's biggest Q2 2024 reduction was Dr. Reddy's Laboratories, cutting an estimated $3.56M.
  • Exome Asset Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $4.64M.
  • Exome Asset Management's ten largest holdings make up 40% of its $112M portfolio in Q2 2024.
  • Exome Asset Management opened 27 new positions and closed 28 in Q2 2024.
  • Exome Asset Management's portfolio value fell 3.8% quarter-over-quarter to $112M.

Based on Exome Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.